Table 3.

Cox proportional hazards regression models of the effect of regular oral antihistamine use on mortality risk, both among all glioma cases and among high-grade glioma cases.

	Cox proportional hazards regression
	HR (95% CI) a
	Overall (n=362)	High-Grade Glioma Only (n=195)
Regular Antihistamine Use
Yes	0.95 (0.65–1.38)	1.07 (0.68–1.67)
No	1.00 (reference)	1.00 (reference)
Self-Reported Allergies/Asthma
Yes	0.76 (0.50–1.14)	0.86 (0.55–1.35)
No	1.00 (reference)	1.00 (reference)
Self-Reported History of Chickenpox
Yes	0.97 (0.71–1.34)	1.08 (0.74–1.57)
No	1.00 (reference)	1.00 (reference)
IgE Levels
≥250 IU per mL	0.81 (0.47–1.40)	0.97 (0.54–1.76)
<250 IU per mL	1.00 (reference)	1.00 (reference)
Sex
Male	1.41 (1.08–1.85)	1.50 (1.08–2.09)
Female	1.00 (reference)	1.00 (reference)
Age
≥ 50 years	3.22 (2.45–4.23)	2.02 (1.44–2.83)
< 50 years	1.00 (reference)	1.00 (reference)
Race
Non-Hispanic White	1.00 (reference)	1.00 (reference)
Other	0.66 (0.43–1.01)	0.63 (0.39–1.04)

Note. IU per mL= International Units per milliliter

^aBolding indicates statistical significance.